The two studies, from teams at NYU Grossman School of Medicine, deployed a technique called SwAP-In to insert 78,000 letters of human DNA code into mouse embryonic stem cells. The inserted DNA included part of the human TAF1 gene and a 'jumping gene' that causes XDP by disrupting that gene's function. In both lab dishes and living mice, the insertion triggered low levels of the TAF1 protein, cell death and holes in the brain, especially in the striatum, a region crucial for movement.
XDP is a neurodegenerative condition with symptoms including slowed movements, tremors, muscle stiffness and involuntary muscle contractions. Symptoms emerge at around age 39 on average, and patients live for 13 to 16 years after onset. Because the underlying mutation is on the X chromosome, the condition affects far more males than females. The mutation first appeared on the island of Panay in the Philippines and, due to a founder effect, is seen only in people of Filipino ancestry. The disease has also carried social stigma, contributing to high rates of depression and suicide among those affected.
In the first study, the team created the mouse model using the SwAP-In method, which allows rewriting large portions of genetic code by inserting synthetic DNA. Study co-author Jef Boeke, director of the Institute for Systems Genetics at NYU and a lead developer of the technique, called it 'a generic method that can be used to make extensively humanized mice.' The mouse version of XDP progresses very quickly, with symptoms appearing in 1.5 months, unlike the years it takes in humans. Boeke said that speed is 'a huge advantage' because it allows experiments on therapeutics.
In the second study, the researchers examined the mice's brain cells and found dramatic changes in glial cells called oligodendrocytes, which produce the fatty insulating material myelin. The researchers found reduced myelin in the striatum and prefrontal cortex. Study co-author Shane Liddelow, an associate professor at NYU, described the tissue as a 'white brain' rather than the normal 'beautiful blue brain.' Further experiments showed the mutation prevented oligodendrocytes from fully maturing, reducing myelin production. The team backed up these findings in brains donated after death by people with XDP.
'This had never been described in this disease before,' Liddelow said. 'It really sort of upended this idea of the disease' as primarily affecting neurons. He added that the finding is 'profoundly important for how you might develop therapies to help these patients.'
The studies suggest several potential treatment ideas, including boosting TAF1 gene activity to raise its protein levels, which showed promise in mouse cell experiments. The second study points to oligodendrocytes as potential targets for future therapies, and myelin loss as a potential early sign of the disease that might be useful for diagnosis. The researchers emphasised that much more remains to be learned, but the new mouse model is now available for other scientists to study the disease.
